{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:47Z","timestamp":1760909267004},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The impact of near-total resection of IDH-mutated anaplastic glioma (IDHmutAG) is well-established but there remains uncertainty of benefit in tumours of the insular cortex where the extent of safe resection may be limited. This study aimed to assess tumour volume reduction in patients following IMRT and impact of residual post-surgical volume.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and materials<\/jats:title>\n                <jats:p>Patients with IDHmutAG involving insular cortex managed with IMRT from 2008 to 2019 had baseline patient, tumour and treatment factors recorded. Volumetric assessment of residual disease on MRI was performed at baseline, month+\u20093 and month+\u200912 post-IMRT. Potential prognostic factors were analysed for tumour reduction and relapse-free survival, and assessed by log-rank and Cox regression analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty two patients with IDHmutAG of the insular cortex were managed with median follow-up post-IMRT of 67.2\u2009months. Pathology was anaplastic astrocytoma (AAmut) in 20, and anaplastic oligodendroglioma (AOD) in 12 patients. Median pre-IMRT volume on T1 and T2Flair was 24.3cm<jats:sup>3<\/jats:sup> and 52.2cm<jats:sup>3<\/jats:sup>. Twenty-seven patients were alive with 5-year relapse-free survival of 80%. There was a median 67 and 64% reduction from baseline occurring at 3\u2009months post-IMRT for T1 and T2Flair respectively; and subsequent median 78 and 73% at 12\u2009months. At 12\u2009months AOD patients had median 83% T1 volume reduction compared to 63% in AAmut (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). There was no difference on T2Flair volume (<jats:italic>p<\/jats:italic>\u2009=\u20090.64). No other pathological factors influenced volume reduction at 12\u2009months. No factors were associated with relapse-free survival including baseline T1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.52) and T2Flair (<jats:italic>p<\/jats:italic>\u2009=\u20090.93) volume.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IMRT provides large tumour volume reduction in IDHmutAG of the insular cortex. While maximal safe debulking remains standard of care when feasible, this patient cohort reported no significant negative impact of residual disease volume on relapse-free survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02548-3","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T14:04:44Z","timestamp":1642514684000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region\u00a0following radiotherapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Gabrielle","family":"Metz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasantha","family":"Jayamanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kastelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Back","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"2548_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in Gliomas. N Engl J Med. 2009;360:765\u201373. https:\/\/doi.org\/10.1056\/NEJMoa0808710.","journal-title":"N Engl J Med"},{"issue":"8","key":"2548_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1200\/JCO.2013.49.3726","volume":"32","author":"JG Cairncross","year":"2014","unstructured":"Cairncross JG, Wang M, Jenkins RB, et al. Benefit from Procarbazine, Lomustine, and vincristine in Oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783\u201390. https:\/\/doi.org\/10.1200\/JCO.2013.49.3726.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2548_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","volume":"129","author":"A Olar","year":"2015","unstructured":"Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129(4):585\u201396. https:\/\/doi.org\/10.1007\/s00401-015-1398-z.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2548_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00401-010-0777-8","volume":"120","author":"P Metellus","year":"2010","unstructured":"Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II Gliomas with dismal prognosis. Acta Neuropathol. 2010;120(6):719\u201329. https:\/\/doi.org\/10.1007\/s00401-010-0777-8.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2548_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1227\/NEU.0000000000000779","volume":"77","author":"CA Racine","year":"2015","unstructured":"Racine CA, Li J, Molinaro AM, Butowski N, Berger MS. Neurocognitive function in newly diagnosed low-grade Glioma patients undergoing surgical resection with awake mapping techniques. Neurosurgery. 2015;77(3):371\u20139. https:\/\/doi.org\/10.1227\/NEU.0000000000000779.","journal-title":"Neurosurgery."},{"issue":"1","key":"2548_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10143-017-0918-9","volume":"41","author":"H Duffau","year":"2018","unstructured":"Duffau H. Is non-awake surgery for supratentorial adult low-grade glioma treatment still feasible? Neurosurg Rev. 2018;41(1):133\u20139. https:\/\/doi.org\/10.1007\/s10143-017-0918-9.","journal-title":"Neurosurg Rev"},{"issue":"1","key":"2548_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00701-012-1541-8","volume":"155","author":"J Martino","year":"2013","unstructured":"Martino J, Gomez E, Bilbao JL, Due\u00f1as JC, V\u00e1zquez-Barquero A. Cost-utility of maximal safe resection of WHO grade II gliomas within eloquent areas. Acta Neurochir. 2013 Jan;155(1):41\u201350. https:\/\/doi.org\/10.1007\/s00701-012-1541-8.","journal-title":"Acta Neurochir"},{"issue":"2","key":"2548_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11060-016-2110-4","volume":"130","author":"SL Hervey-Jumper","year":"2016","unstructured":"Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neuro-Oncol. 2016;130(2):269\u201382 Epub 2016 May 12. Review. PMID:27174197.","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"2548_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11060-015-1867-1","volume":"125","author":"MK Aghi","year":"2015","unstructured":"Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2015;125(3):503\u201330. https:\/\/doi.org\/10.1007\/s11060-015-1867-1.","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"2548_CR10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/neuros\/nyx265","volume":"82","author":"T Patel","year":"2017","unstructured":"Patel T, Bander ED, Venn RA, et al. The role of extent of resection in IDH1 wild-type or mutant low-grade Gliomas. Neurosurgery. 2017;82(6):808\u201314. https:\/\/doi.org\/10.1093\/neuros\/nyx265.","journal-title":"Neurosurgery."},{"issue":"5","key":"2548_CR11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/neuonc\/noaa225","volume":"23","author":"M Rossi","year":"2021","unstructured":"Rossi M, Gay L, Ambrogi F, Nibali MC, Sciortino T, Puglisi G, et al. Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro-Oncology. 2021;23(5):812\u201326. https:\/\/doi.org\/10.1093\/neuonc\/noaa225.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"2548_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2009.6.JNS0952","volume":"112","author":"M Berger","year":"2010","unstructured":"Berger M, Sanai PM. Insular glioma resection: assessment of patient morbidity, survival and tumour progression. J Neurosurg. 2010;112(1):1\u20139. https:\/\/doi.org\/10.3171\/2009.6.JNS0952.","journal-title":"J Neurosurg"},{"issue":"1","key":"2548_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13014-017-0782-3","volume":"12","author":"M Back","year":"2017","unstructured":"Back M, LeMottee M, Crasta C, et al. Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma. Radiat Oncol. 2017;12(1):46. https:\/\/doi.org\/10.1186\/s13014-017-0782-3.","journal-title":"Radiat Oncol"},{"key":"2548_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12885-016-2399-6","volume":"16","author":"P Navarria","year":"2016","unstructured":"Navarria P, Pessina F, Cozzi L, et al. Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? Analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy. BMC Cancer. 2016;16:362. https:\/\/doi.org\/10.1186\/s12885-016-2399-6.","journal-title":"BMC Cancer"},{"issue":"3","key":"2548_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.radonc.2010.08.001","volume":"96","author":"AL Grosu","year":"2010","unstructured":"Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol. 2010;96(3):325\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2010.08.001.","journal-title":"Radiother Oncol"},{"key":"2548_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jocn.2018.11.005","volume":"15","author":"M Back","year":"2018","unstructured":"Back M, Jayamanne D, Brazier D, Hsiao E, Guo L, Wheeler W. Tumour volume reduction following PET guided intensity modulated image-guided radiotherapy and temozoloamide in IDH mutated anaplastic glioma. J Clin Neurosci. 2018;15:68\u201374. https:\/\/doi.org\/10.1016\/j.jocn.2018.11.005.","journal-title":"J Clin Neurosci"},{"issue":"2","key":"2548_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97\u2013109. https:\/\/doi.org\/10.1007\/s00401-007-0243-4.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2548_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320. https:\/\/doi.org\/10.1007\/s00401-016-1545-1.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2548_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3171\/2015.4.JNS1521","volume":"124","author":"M Berger","year":"2016","unstructured":"Berger M, Hervery-Jumper SL, et al. Surgical assessment of the sinula. Part 2: validation of the Berger-Sanai zone classification system for predicting extent of glioma resection. J Neurosurg. 2016;124(2):428. https:\/\/doi.org\/10.3171\/2015.4.JNS1521.","journal-title":"J Neurosurg"},{"key":"2548_CR20","doi-asserted-by":"publisher","unstructured":"Van Den Bent MJ, Erridge S, Vogelbaum M, et al. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p\/19q co-deletion: an intergroup trial. J Clin Oncol. 2016;34. https:\/\/doi.org\/10.1200\/JCO.2016.34.18_suppl.LBA200.","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA200"},{"issue":"3","key":"2548_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337\u201343. https:\/\/doi.org\/10.1200\/JCO.2012.43.2674.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2548_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ van den Bent","year":"2013","unstructured":"van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344\u201350. https:\/\/doi.org\/10.1200\/JCO.2012.43.2229.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2548_CR23","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","volume":"35","author":"P Wen","year":"2017","unstructured":"Wen P, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in Neuro-oncology clinical trials. J Clin Oncol. 2017;35(21):2439\u201349. https:\/\/doi.org\/10.1200\/JCO.2017.72.7511.","journal-title":"J Clin Oncol"},{"issue":"33","key":"2548_CR24","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1200\/JCO.2016.67.1222","volume":"34","author":"C Choi","year":"2016","unstructured":"Choi C, Raisanen JM, Ganji SK, et al. Prospective longitudinal analysis of 2-Hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the Management of Patients with IDH-mutant Glioma. J Clin Oncol. 2016;34(33):4030\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.67.1222.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2548_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/neuonc\/now121","volume":"19","author":"B Zhang","year":"2017","unstructured":"Zhang B, Chang K, Ramkissoon S, et al. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro-Oncology. 2017;19(1):109\u201317. https:\/\/doi.org\/10.1093\/neuonc\/now121.","journal-title":"Neuro-Oncology"},{"issue":"4","key":"2548_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.2967\/jnumed.111.097352","volume":"53","author":"A Heinzel","year":"2012","unstructured":"Heinzel A, Stock S, Langen KJ, M\u00fcller D. Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas. J Nucl Med. 2012;53(4):552\u20138. https:\/\/doi.org\/10.2967\/jnumed.111.097352.","journal-title":"J Nucl Med"},{"issue":"10","key":"2548_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11940-017-0469-y","volume":"19","author":"A Castellano","year":"2017","unstructured":"Castellano A, Cirillo S, Bello L, Riva M, Falini A. Functional MRI for surgery of Gliomas. Curr Treat Options Neurol. 2017;19(10):34. https:\/\/doi.org\/10.1007\/s11940-017-0469-y.","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"2548_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1227\/01.neu.0000318159.21731.cf","volume":"62","author":"N Sanai","year":"2008","unstructured":"Sanai N, Berger M. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753\u201364. https:\/\/doi.org\/10.1227\/01.neu.0000318159.21731.cf.","journal-title":"Neurosurgery."},{"issue":"1","key":"2548_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/neuonc\/nox176","volume":"20","author":"MMJ Wijnenga","year":"2018","unstructured":"Wijnenga MMJ, French PJ, Dubbink HJ, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology. 2018;20(1):103\u201312. https:\/\/doi.org\/10.1093\/neuonc\/nox176.","journal-title":"Neuro-Oncology"},{"issue":"8","key":"2548_CR30","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","volume":"28","author":"AS Jakola","year":"2017","unstructured":"Jakola AS, Skjulsvik AJ, Myrmel KS, Sj\u00e5vik K, Unsg\u00e5rd G, Torp SH, et al. Surgical resection versus watchful waiting in low-grade Gliomas. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2017;28(8):1942\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdx230.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"3","key":"2548_CR31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-019-03261-5","volume":"144","author":"CJ Kinslow","year":"2019","unstructured":"Kinslow CJ, Garton ALA, Rae AI, Marcus LP, Adams CM, McKhann GM, et al. Extent of resection and survival for Oligodendroglioma: a U.S. population-based study. J Neuro-Oncol. 2019;144(3):591\u2013601. https:\/\/doi.org\/10.1007\/s11060-019-03261-5.","journal-title":"J Neuro-Oncol"},{"issue":"9343","key":"2548_CR32","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/s0140-6736(02)11398-5","volume":"360","author":"M Klein","year":"2002","unstructured":"Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360(9343):1361\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(02)11398-5.","journal-title":"Lancet."},{"issue":"6","key":"2548_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3171\/2012.8.JNS12393","volume":"117","author":"M Skrap","year":"2012","unstructured":"Skrap M, Ius T, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single institution experience in 190 patients. J Neurosurg. 2012;117(6):1039\u201352. https:\/\/doi.org\/10.3171\/2012.8.JNS12393.","journal-title":"J Neurosurg"},{"key":"2548_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.radonc.2021.04.023","volume":"160","author":"C Koutsarnakis","year":"2021","unstructured":"Koutsarnakis C, Neromyliotis E, et al. Effects of brain radiotherapy on cognitive performance in adult low-grade glioma patients: a systematic review. Radiother Oncol. 2021;160:202\u201311. https:\/\/doi.org\/10.1016\/j.radonc.2021.04.023.","journal-title":"Radiother Oncol"},{"issue":"2","key":"2548_CR35","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/1754-9485.12850","volume":"63","author":"M Back","year":"2019","unstructured":"Back M, Jayamanne DT, Brazier D, et al. Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. J Med Imaging Radiat Oncol. 2019;63(2):272\u201380. https:\/\/doi.org\/10.1111\/1754-9485.12850.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"12","key":"2548_CR36","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/noz124","volume":"21","author":"R Appay","year":"2019","unstructured":"Appay R, Dehais C, Maurage CA, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology. 2019;21(12):1519\u201328. https:\/\/doi.org\/10.1093\/neuonc\/noz124.","journal-title":"Neuro-Oncology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02548-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T09:20:10Z","timestamp":1644225610000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02548-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2548"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02548-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data for this study was stored and retrieved from an Ethics approved prospective database approved by the Northern Sydney Local Health District Human Research Ethics Committee (reference LNR\/15\/HAWKE355). All methods were performed in accordance with relevant guidelines and regulations and approved by this committee. Informed consent to participate was obtained from all participants via a clearly stated opt out procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}